JP6483083B2 - 治療用化合物の眼への送達を増強する方法 - Google Patents

治療用化合物の眼への送達を増強する方法 Download PDF

Info

Publication number
JP6483083B2
JP6483083B2 JP2016502078A JP2016502078A JP6483083B2 JP 6483083 B2 JP6483083 B2 JP 6483083B2 JP 2016502078 A JP2016502078 A JP 2016502078A JP 2016502078 A JP2016502078 A JP 2016502078A JP 6483083 B2 JP6483083 B2 JP 6483083B2
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
plasmin
retinal
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519063A5 (https=
JP2016519063A (ja
Inventor
チュオ−ホア パン
チュオ−ホア パン
エレナ イワノワ
エレナ イワノワ
Original Assignee
ウェイン ステイト ユニバーシティー
ウェイン ステイト ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイン ステイト ユニバーシティー, ウェイン ステイト ユニバーシティー filed Critical ウェイン ステイト ユニバーシティー
Publication of JP2016519063A publication Critical patent/JP2016519063A/ja
Publication of JP2016519063A5 publication Critical patent/JP2016519063A5/ja
Application granted granted Critical
Publication of JP6483083B2 publication Critical patent/JP6483083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016502078A 2013-03-14 2014-03-13 治療用化合物の眼への送達を増強する方法 Active JP6483083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785015P 2013-03-14 2013-03-14
US61/785,015 2013-03-14
PCT/US2014/026224 WO2014160281A2 (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018228150A Division JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法

Publications (3)

Publication Number Publication Date
JP2016519063A JP2016519063A (ja) 2016-06-30
JP2016519063A5 JP2016519063A5 (https=) 2017-04-13
JP6483083B2 true JP6483083B2 (ja) 2019-03-13

Family

ID=50687629

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502078A Active JP6483083B2 (ja) 2013-03-14 2014-03-13 治療用化合物の眼への送達を増強する方法
JP2018228150A Pending JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法
JP2020188684A Pending JP2021038240A (ja) 2013-03-14 2020-11-12 治療用化合物の眼への送達を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018228150A Pending JP2019055980A (ja) 2013-03-14 2018-12-05 治療用化合物の眼への送達を増強する方法
JP2020188684A Pending JP2021038240A (ja) 2013-03-14 2020-11-12 治療用化合物の眼への送達を増強する方法

Country Status (6)

Country Link
US (3) US9730888B2 (https=)
EP (1) EP2968476B1 (https=)
JP (3) JP6483083B2 (https=)
AU (2) AU2014243925B2 (https=)
CA (1) CA2903545C (https=)
WO (1) WO2014160281A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184212A (ja) * 2021-05-31 2022-12-13 ユニ・チャーム株式会社 月経血を吸収するための吸収性物品

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
CA3034887A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
US11932679B2 (en) * 2016-09-02 2024-03-19 Keio University Agent for restoring visual function or agent for preventing deterioration in visual function
US11261236B2 (en) 2017-01-06 2022-03-01 Kyungpook National University Industry-Academic Cooperation Foundation Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
WO2018181071A1 (ja) * 2017-03-28 2018-10-04 森永乳業株式会社 非コラーゲン性糖タンパク質分解用組成物
JP2022533645A (ja) * 2019-05-17 2022-07-25 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
JPWO2021049634A1 (https=) 2019-09-13 2021-03-18
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
US20250186617A1 (en) * 2020-09-17 2025-06-12 Restore Vision Inc. Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness
CN113355309B (zh) * 2021-08-10 2021-11-05 迈威(上海)生物科技股份有限公司 重组截短型人纤维蛋白溶酶制备工艺
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20080248021A1 (en) 2005-06-30 2008-10-09 Ista Pharmaceuticals, Inc. Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2009067407A2 (en) 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
AU2013230112A1 (en) 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022184212A (ja) * 2021-05-31 2022-12-13 ユニ・チャーム株式会社 月経血を吸収するための吸収性物品

Also Published As

Publication number Publication date
WO2014160281A3 (en) 2015-04-09
AU2014243925A1 (en) 2015-10-08
JP2016519063A (ja) 2016-06-30
HK1220625A1 (zh) 2017-05-12
EP2968476A2 (en) 2016-01-20
JP2021038240A (ja) 2021-03-11
US20160038409A1 (en) 2016-02-11
JP2019055980A (ja) 2019-04-11
AU2014243925B2 (en) 2018-12-06
US20200268647A1 (en) 2020-08-27
WO2014160281A2 (en) 2014-10-02
US20180064640A1 (en) 2018-03-08
EP2968476B1 (en) 2021-05-05
CA2903545A1 (en) 2014-10-02
AU2019201474A1 (en) 2019-03-28
US9730888B2 (en) 2017-08-15
CA2903545C (en) 2022-09-06

Similar Documents

Publication Publication Date Title
JP6483083B2 (ja) 治療用化合物の眼への送達を増強する方法
US11883463B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US12343408B2 (en) AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
JP6240067B2 (ja) 光感受性キメラｇｐｃｒタンパク質
US20230159609A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
CN111378020A (zh) 通道视蛋白-2(Chop2)突变的鉴定及使用方法
Nikonov et al. Restoration of vision and retinal responses after adeno-associated virus–mediated optogenetic therapy in blind dogs
EP3892738A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
CN118662606A (zh) 新型光敏感离子通道蛋白ChRmine在视网膜神经退行性疾病中的应用
HK1220625B (en) A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
JP7792699B2 (ja) 改変チャネルロドプシン
US20260048089A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
HK40004342A (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190213

R150 Certificate of patent or registration of utility model

Ref document number: 6483083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250